<DOC>
	<DOCNO>NCT00530335</DOCNO>
	<brief_summary>The objective ass overall safety tolerability atomoxetine dose 120 mg/day Japanese adult patient meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM-IV ) criterion ADHD</brief_summary>
	<brief_title>Atomoxetine Phase 2 Study Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>least 18 year age meet Conners ' Adult ADHD Diagnostic Interview DSMIVâ„¢ ( CAADID ) diagnostic criterion current ADHD well meet criterion historical diagnosis ADHD childhood Clinical Global ImpressionADHDSeverity ( CGIADHDS ) score 4 ( moderate symptom ) great Patients meet DSMIV diagnostic criterion current major depression also patient total score 12 Hamilton Depression Rating Scale17 item ( HAMD17 ) Visit 1 Visit 2 . Patients current past history major depression receive antidepression drug therapy within 6 month Visit 1 . Patients meet DSMIV diagnostic criterion current anxiety disorder also require antianxiety drug therapy except take benzodiazepine analogue anxiety need limit . Patients history bipolar disorder ( DSMIV ) , history schizophrenia history psychotic disorder ( DSMIV ) exclude study . Patients diagnose ( DSMIV ) pervasive developmental disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>